What does this research mean for the field?

Once-weekly tirzepatide combined with personalized lifestyle modification significantly improves adiposity and glycemic control while reducing the need for other diabetes medications in a real-world Indian population with type 2 diabetes and obesity. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This study aims to evaluate the effects of tirzepatide combined with lifestyle modifications on weight and glycemic parameters in individuals with diabetes and obesity.

June 7, 2026

1677-P: Real-World Outcomes of Tirzepatide Combined with Personalized Lifestyle Modification in an Indian Population with Diabetes and Obesity

Key Points

This study aims to evaluate the effects of tirzepatide combined with lifestyle modifications on weight and glycemic parameters in individuals with diabetes and obesity.
Retrospective analysis of 170 adults with T2D receiving tirzepatide and lifestyle interventions.
Outcomes evaluated at 12, 8, and 4 weeks after starting tirzepatide.
Changes in BMI, weight, waist circumference, fasting blood sugar, and postprandial blood sugar were monitored.
After 12 weeks, BMI decreased by 1.16 kg/m2, weight by 3.73 kg, waist circumference by 2.19 cm, fasting blood sugar by 22.34 mg/dL, and postprandial blood sugar by 52.63 mg/dL (all p<0.05).
Medication intensity decreased by 32.08% after 12 doses, 53.97% after 8 doses, and 41.87% after 4 doses (all p<0.05).

Abstract

Introduction and Objective: Weight loss and glycemic improvement with incretin-based therapies evolve over time and are influenced by both pharmacologic exposure and lifestyle adherence. Repeated once-weekly tirzepatide dosing plus lifestyle management allows the temporal pattern of glycemic and anthropometric change to be defined. This study aimed to assess progressive changes in weight, central adiposity, glycemic parameters, and reduction in medication with tirzepatide plus lifestyle support. Methods: This retrospective real-world study included 170 adults with T2D receiving once-weekly tirzepatide plus personalized, structured dietary and physical activity interventions. Outcomes were assessed for 12-, 8-, and 4-weekly tirzepatide exposure groups (Months 3, 2, and 1; n=21, 35, and 114, respectively), with changes in body mass index (BMI), body weight, waist circumference (WC), fasting blood sugar (FBS), postprandial blood sugar (PPBS), and medication intensity assessed at each exposure timepoint. Results: Administration of tirzepatide with lifestyle support showed progressive metabolic improvements with BMI (kg/m2), weight (kg), WC (cm), FBS (mg/dL), and PPBS (mg/dL) decreasing by 1.16±0.90, 3.73±2.44, 2.19±0.27, 22.34±24.69, and 52.63±48.02 after 12 weekly doses; 1.36±1.81, 4.29±4.96, 4.25±3.03, 28.28±39.08, and 29.52±27.88 after 8 weekly doses; 1.17±1.73, 3.09±3.25, 3.05±1.67, 16.11±32.96, and 21.89±34.40 after 4 weekly doses, respectively (all p0.05). The medications also declined across 12-, 8-, and 4-dose exposure groups, with intensity of pharmacotherapy improving as medication burden decreased by 32.08%, 53.97%, and 41.87%, respectively (all p0.05). Conclusion: Once-weekly tirzepatide, when paired with personalized lifestyle modification, delivered clinically meaningful improvements in adiposity, glycemic control, and reduced diabetes medication needs in routine Indian practice, reinforcing the value of integrated metabolic therapy. Disclosure C.G. Mehra: None. A.M. Raymond: None. A. Sequeira: None. J. Joseline: None. S. Kumar: None.

اسأل الذكاء الاصطناعي

Bookmark